Kolejna zagraniczna firma zainwestuje w województwie opolskim, dzięki wsparciu udzielonemu przez Wałbrzyską Specjalną Strefę Ekonomiczną "INVEST-PARK" Firma CAREL SYSTEMS sp. z o.o. (należąca do włosk ...

To establish an operational presence in the U.S., reinsurance broker Willis Re on Aug. 18 said it is acquiring BMS Re, US. The deal includes BMS Intermediaries Inc. and BMS Capital Advisory LLC, as ...

Willis Re, the reinsurance business of Willis Towers Watson, said Tuesday it has agreed to acquire the U.S. division of BMS Re, the reinsurance brokerage arm of London-based BMS Group, in a deal that ...

UK drugmaker AstraZeneca is in talks to combine with US rival Bristol Myers Squibb in a deal that would create one of the world’s biggest pharmaceutical groups, valued at nearly $400bn. The companies ...

BMS is deploying an NVIDIA supercomputer to enhance its AI infrastructure. Credit: Blue Andy / Shutterstock.com. Bristol Myers Squibb (BMS) has further established itself on the growing list of big ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint from NVIDIA, saying it will deliver a "step change" in computational power ...

It’s officially a trend. For the third time in nine months, a pharma company has announced that it is assembling the largest AI supercomputer in the life sciences industry. This time, it is Bristol ...

BMS' first-quarter revenues climbed 3% to $11.5 billion, with $6.2 billion of the haul coming from its newer growth product portfolio. (Angus Liu/Fierce Pharma) Bristol Myers Squibb’s growth portfolio ...

Carel Pedre, a popular TV and radio host from Haiti, was arrested in Tamarac, Florida, on domestic violence allegations, jail records from Broward County showed. He was arrested on December 21, Sunday ...

Phone recording between Auckland businessman Carel Vijoen and a Westpac bank employee discussing suspicious transactions in and out of his account. A respected Auckland professional who played a key ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...